Skip to main content

Table 2 Characteristics of 90 children in an age matched control group at 11 years of age, according to asthma and atopy

From: Exhaled nitric oxide is related to atopy, but not asthma in adolescents with bronchiolitis in infancy

  Healthy (n = 51) Atopic non-asthmatic (n = 29) P-value Current non-atopic asthma (n = 5) P-value Current atopic asthma (n = 5) P-value
Boys, n (%) 31 (61) 16 (55) 0.644 4 (80) 0.640 4 (80) 0.640
Age at follow up* (year) 11.8 (11.4, 12.2) 11.4 (11.0, 12.1) 0.081 12.3 (11.4, 12.8) 0.147 11.8 (10.9, 12.0) 0.502
Weight at follow-up (kg) 41.7 (8.5) 40.9 (9.4) 0.677 47.9 (17.3) 0.472 51.4 (25.7) 0.449
Height at follow-up (cm) 151.9 (7.6) 149.0 (7.0) 0.087 150.8 (10.2) 0.749 152.0 (17.1) 0.998
ICS, n (%) 1 (2) 0 1.000 3 (60) 0.001 4 (80) <0.001
FEV1% 98.7 (10.6) 99.8 (7.9) 0.631 101.9 (10.7) 0.510 96.3 (28.3) 0.864
FEF25–75% 96.9 (22.9) 98.9 (16.1) 0.693 95.6 (18.9) 0.903 93.3 (45.7) 0.764
FEV1 /FVC ratio 84.3 (6.6) 84.2 (4.5) 0.969 79.8 (4.2) 0.146 80.8 (6.7) 0.269
DRS to methacholine* 1.7 (1.0, 6.8) 3.6 (0.8,17.6) 0.084 0.9 (0.3, 5.8) 0.292 4.7 (1.1, 24.5) 0.405
  1. *Median (inter quartile range), mean (standard deviation). ICS, inhaled corticosteroids last 12 months before follow up; FEV1%, forced expiratory volume in first second as percentage of predicted; FEF25–75%, forced expiratory flow between 25-75% of the forced vital capacity (FVC) as percentage of predicted; DRS, dose response slope. For missing data, see text. P-values assess comparisons with the healthy group.
  2. Bold values indicate significance at the 0.05 level.